BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
+2.17%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$1.32B
AUM Growth
+$1.32B
(-0.64%)
Cap. Flow
+$7.14M
Cap. Flow
% of AUM
0.54%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$7.14M |
| 2 |
STAAR Surgical
STAA
|
$48 |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 43.07% |
| 2 | Consumer Staples | 31.33% |
| 3 | Industrials | 16.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
STAAR Surgical
STAA
$1.36B
| $513M | 38.77% | 10,768,431 +1 | +0% | +$48 |
|
2
Monster Beverage
MNST
$60.9B
| $414M | 31.33% | 8,295,690 | – | – |
|
3
Axon Enterprise
AXON
$58.7B
| $224M | 16.91% | 760,062 | – | – |
|
4
iShares Russell 2000 ETF
IWM
$67B
| $115M | 8.68% | 566,000 | – | – |
|
5
Lineage Cell Therapeutics
LCTX
$267M
| $41.6M | 3.14% | 41,666,255 | – | – |
|
|
IMDX
6
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $14.5M | 1.1% | 4,929,066 +2,420,000 | +96% | +$7.14M |
|
7
Serina Therapeutics
SER
$54.5M
| $816K | 0.06% | 85,219 | – | – |
|